2026年新药批准
正文 · 中文译文
2026年新药批准 FDA的新药批准 2026年新药批准 2025年新药批准 2024年新药批准 2023年新药批准 2022年新药批准 2021年新药批准 什么是“新”药? “新”药是指此前从未在美国获批或上市的新药。有关CDER所有已批准药物和生物制品的相关信息,请参见Drugs@FDA。 FDA 2026年新型药物治疗批准 序号 药物名称 活性成分 批准日期 FDA批准日期时的获批用途* 48.Sunharboasundexian 11/9/2026 用于降低近期发生轻至中度非心源性缺血性卒中或高危短暂性脑缺血发作后成人卒中的风险 47.Hibsagobepirovirsen 10/20/2026 用于治疗某些无肝硬化的成人慢性乙型肝炎病毒感染,与现有抗病毒治疗联合使用 46.Hovilpripritelivir 10/9/2026 用于治疗免疫功能减弱且患有由单纯疱疹病毒感染引起、且对其他治疗无应答的皮肤黏膜病变的成人 45.Emcitatetiratricol 9/28/2026 用于治疗MCT8缺乏症患者的外周性甲状腺毒症 44.Atebrioz zilurgisertib 9/25/2026 用于减少12岁及以上成人和儿童进行性骨化性纤维发育不良患者新增异位骨化总体积 43.Juvmotavapadon 9/25/2026 用于治疗成人帕金森病 42.Lyrfigtulirafugratinib 2026年9月23日 用于既往接受过治疗、不可切除、局部晚期或转移性、携带成纤维细胞生长因子受体2基因融合或其他重排的胆管癌成人患者 41.Onswikinsulin efsitora alfa-gobe 2026年9月23日 用于改善2型糖尿病成人患者的血糖控制,作为饮食和运动的辅助治疗 40.Pixclarafloretyrosine F 18 2026年9月11日 与其他诊断评估联合用于正电子发射断层扫描,以区分复发性或进展性胶质瘤与治疗相关改变 39.Isembyldapitegromab-mstn 2026年9月11日 用于治疗目前正在接受SMN2靶向治疗的2岁及以上成人和儿童患者的脊髓性肌萎缩症 38.Etcamahcamizestrant 2026年9月4日 用于治疗激素受体阳性、人表皮生长因子受体2阴性、局部晚期或转移性乳腺癌,适用于在芳香化酶抑制剂和CDK4/6抑制剂治疗期间检测到ESR1突变的患者 37.Zanvastrozilganersen 2026年9月3日 用于治疗儿童和成人患者的亚历山大病 36.Mimrylorusfertide 2026年8月28日 用于治疗真性红细胞增多症成人患者的红细胞增多症 35.Lisrayabrepocitinib 2026年8月27日 用于治疗成人皮肌炎 34.Rasonquedaraxonrasib 2026年8月26日 用于治疗转移性胰腺癌 33.Pasatrugaretosmab-grts 2026年8月19日 用于减少进行性骨化性纤维发育不良成人患者的新发异位骨化和临床医生评估的疾病发作 32.Zenbexusiberdomide 8/13/2026 与达雷妥尤单抗(daratumumab)和透明质酸酶-fihj及地塞米松联合使用,用于已接受至少一线既往治疗(包括蛋白酶体抑制剂和免疫调节剂)的成人多发性骨髓瘤患者 31.Tauklarifyflorquinitau F 18 8/13/2026 用于正在接受阿尔茨海默病评估的认知障碍成人脑部正电子发射断层扫描,以识别具有tau神经原纤维缠结病理的患者 30.Orzeyfuloveporexton 8/5/2026 用于治疗1型发作性睡病 29.Simtriyocentanafadine 7/24/2026 用于治疗注意缺陷多动障碍 28.Lytenavabevacizumab-vikg 7/24/2026 用于治疗新生血管性(湿性)年龄相关性黄斑变性患者 27.Jideytrozidesamtinib 7/22/2026 用于治疗在接受ROS1激酶抑制剂后出现局部晚期或转移性ROS1阳性非小细胞肺癌的成人患者 26.Lipfendraenlicitide decanoate 7/15/2026 用于降低低密度脂蛋白胆固醇 25.Revtorpykgedatolisib 7/14/2026 与氟维司群(fulvestran)联合使用,用于治疗激素受体阳性、人表皮生长因子受体2阴性、未检测到PIK3CA突变的局部晚期或转移性乳腺癌,且在转移阶段接受至少一线内分泌治疗后进展或之后 24.Trutaknaatacicept-vymj 7/7/2026 用于减少有疾病进展风险的原发性免疫球蛋白A肾病成人患者的蛋白尿 23.Lumvoaveligrotug-vvze 6/26/2026 用于治疗甲状腺眼病 22. 特比萘芬 pivoxil?6/17/2026 用于治疗成人复杂性尿路感染(包括肾盂肾炎),致病菌为多种敏感微生物,且患者口服替代治疗方案有限或无替代方案 21. Ambelvistgadoquatrane 6/12/2026 与MRI联合用于检测和显示血管分布异常的病变 20. Cypsedocipepofol 5/29/2026 用于接受手术的成人全身麻醉诱导 19. Xocovaensitrelvir 5/29/2026 用于接触2019冠状病毒病(COVID-19)患者后的COVID-19暴露后预防 18. Zaynichcefepime和zidebactam 5/29/2026 用于治疗由指定敏感微生物引起的复杂性尿路感染(包括肾盂肾炎) 17. Decnupazpivekimab sunirine-pvzy 5/27/2026 用于治疗成人母细胞性浆细胞样树突状细胞肿瘤 药物试验快照 16. Hepcludexbulevirtide-gmod 5/22/2026 用于治疗无肝硬化或代偿期肝硬化成人的慢性丁型肝炎病毒感染 15. Baxfendybaxdrostat 5/15/2026 与其他降压药联合用于治疗高血压 14. Beqalzisonrotoclax 5/13/2026 用于治疗成人复发或难治性套细胞淋巴瘤,患者此前至少接受过两线全身治疗(包括布鲁顿酪氨酸激酶抑制剂) 13. Veppanuvepdegestrant 5/1/2026 用于治疗雌激素受体阳性、人表皮生长因子受体2阴性、ESR1突变的晚期或转移性乳腺癌,且患者至少接受过一线内分泌治疗后出现疾病进展 12.Idvynsodoravirine和islatravir 4/20/2026 用于治疗成人HIV-1感染(作为完整方案),以替代当前抗逆转录病毒方案,适用于在稳定抗逆转录病毒方案下病毒学抑制、无病毒学治疗失败史且无已知与doravirine耐药相关替换的患者 11.Foundayoorforglipron 4/1/2026 用于减轻超重体重并长期维持体重减轻,适用于肥胖成人或至少伴有一种体重相关合并症的超重成人,联合低热量饮食和增加体力活动 10.Awiqliinsulin icodec-abae 3/26/2026 用于改善成人2型糖尿病患者的血糖控制 9.Lifyorlirelacorilant 3/25/2026 用于治疗铂耐药性上皮性卵巢癌、输卵管癌或原发性腹膜癌,在接受过一至三种既往全身治疗方案后,其中至少一种方案包含bevacizumab 8.Avlayahtividenofusp alfa-eknm 3/24/2026 用于治疗某些Hunter综合征(黏多糖贮积症II型或MPS II)患者 7.Icotydeicotrokinra 3/17/2026 用于治疗12岁及以上、体重至少40 kg且适合系统性治疗或光疗的中重度斑块状银屑病患者 药物试验快照 6.Lynavoylinerixibat 3/17/2026 用于治疗与原发性胆汁性胆管炎相关的胆汁淤积性瘙痒 5.Yuviwelnavepegritide 2/27/2026 用于促进2岁及以上骨骺未闭合的软骨发育不全儿科患者的线性生长 4.Loargyspegzilarginase-nbln2/23/2026用于治疗两岁及以上成人和儿童精氨酸酶1缺乏症患者的高精氨酸血症,结合饮食蛋白限制 3.Bysantimilsaperidone2/20/2026用于治疗精神分裂症以及治疗与双相I型障碍相关的躁狂或混合发作 2.Adqueydifamilast2/12/2026用于治疗轻至中度特应性皮炎 1.Zycubocopper histidinate1/12/2026用于治疗门克斯病 药物试验快照 *本页列出的“FDA批准用途”仅供展示目的。要查看每种产品的FDA批准使用条件[例如,适应症、人群、给药方案],请参阅Drugs@FDA上可获得的最新批准的处方信息(或标签)。您可以通过药物名称、活性成分或申请编号进行搜索。 内容截至日期: 11/09/2026 受监管产品 药物
正文 · 英文原文
Novel Drug Approvals for 2026 Novel Drug Approvals at FDA Novel Drug Approvals for 2026 Novel Drug Approvals for 2025 Novel Drug Approvals for 2024 Novel Drug Approvals for 2023 Novel Drug Approvals for 2022 Novel Drug Approvals for 2021 What are "Novel" Drugs? "Novel" drugs are new drugs never before approved or marketed in the U.S. See Drugs@FDA for information about all of CDER’s approved drugs and biological products. FDA Novel Drug Therapy Approvals for 2026 No.Drug NameActive IngredientApproval DateFDA-approved use on approval date* 48.Sunharboasundexian11/9/2026To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack 47.Hibsagobepirovirsen 10/20/2026To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy 46.Hovilpripritelivir10/9/2026To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies 45.Emcitatetiratricol9/28/2026To treat peripheral thyrotoxicosis in patients with MCT8 deficiency 44.Atebrioz zilurgisertib9/25/2026To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva 43.Juvmotavapadon9/25/2026To treat Parkinson’s disease in adults 42.Lyrfigtulirafugratinib9/23/2026To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement 41.Onswikinsulin efsitora alfa-gobe9/23/2026To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise 40.Pixclarafloretyrosine F 189/11/2026To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations 39.Isembyldapitegromab-mstn9/11/2026To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment 38.Etcamahcamizestrant9/4/2026To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy 37.Zanvastrozilganersen9/3/2026To treat Alexander disease in pediatric and adult patients 36.Mimrylorusfertide8/28/2026To treat erythrocytosis in adults with polycythemia vera 35.Lisrayabrepocitinib8/27/2026To treat dermatomyositis in adults 34.Rasonquedaraxonrasib8/26/2026To treat metastatic pancreatic cancer 33.Pasatrugaretosmab-grts8/19/2026To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva 32.Zenbexusiberdomide8/13/2026To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent 31.Tauklarifyflorquinitau F 188/13/2026To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology 30.Orzeyfuloveporexton8/5/2026To treat narcolepsy type 1 29.Simtriyocentanafadine7/24/2026To treat attention-deficit hyperactivity disorder 28.Lytenavabevacizumab-vikg7/24/2026To treat patients with neovascular (wet) age-related macular degeneration 27.Jideytrozidesamtinib7/22/2026To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor 26.Lipfendraenlicitide decanoate7/15/2026To reduce low-density lipoprotein cholesterol 25.Revtorpykgedatolisib7/14/2026In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting 24.Trutaknaatacicept-vymj7/7/2026To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression 23.Lumvoaveligrotug-vvze6/26/2026To treat thyroid eye disease 22.Utebzitebipenem pivoxil6/17/2026To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options 21.Ambelvistgadoquatrane6/12/2026To detect and visualize lesions with abnormal vascularity, in conjunction with MRI 20.Cypsedocipepofol5/29/2026To induce general anesthesia in adults undergoing surgery 19.Xocovaensitrelvir5/29/2026To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19 18.Zaynichcefepime and zidebactam5/29/2026To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms 17.Decnupazpivekimab sunirine-pvzy5/27/2026To treat adults with blastic plasmacytoid dendritic cell neoplasm Drug Trials Snapshot 16.Hepcludexbulevirtide-gmod5/22/2026To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis 15.Baxfendybaxdrostat5/15/2026To treat hypertension in combination with other antihypertensive drugs 14.Beqalzisonrotoclax5/13/2026To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor 13.Veppanuvepdegestrant5/1/2026To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy 12.Idvynsodoravirine and islatravir4/20/2026To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine 11.Foundayoorforglipron4/1/2026To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity 10.Awiqliinsulin icodec-abae3/26/2026To improve glycemic control in adults with type 2 diabetes mellitus 9.Lifyorlirelacorilant3/25/2026To treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens, at least one of which included bevacizumab 8.Avlayahtividenofusp alfa-eknm3/24/2026To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II) 7.Icotydeicotrokinra3/17/2026To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy Drug Trials Snapshot 6.Lynavoylinerixibat3/17/2026To treat cholestatic pruritus associated with primary biliary cholangitis 5.Yuviwelnavepegritide2/27/2026To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses 4.Loargyspegzilarginase-nbln2/23/2026To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction 3.Bysantimilsaperidone2/20/2026To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder 2.Adqueydifamilast2/12/2026To treat mild to moderate atopic dermatitis 1.Zycubocopper histidinate1/12/2026To treat Menkes disease Drug Trials Snapshot *The listed “FDA-approved use” on this page is for presentation purposes only. To see the FDA-approved conditions of use [e.g., indication(s), population(s), dosing regimen(s)] for each of these products, please see the most recently approved Prescribing Information (or Label) available at Drugs@FDA. You can search by drug name, active ingredient, or application number. Content current as of: 11/09/2026 Regulated Product(s) Drugs